<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02677207</url>
  </required_header>
  <id_info>
    <org_study_id>JNJ-DEP</org_study_id>
    <nct_id>NCT02677207</nct_id>
  </id_info>
  <brief_title>The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive</brief_title>
  <acronym>JNJ-DEP</acronym>
  <official_title>The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive Symptoms in 80 Patients With Unipolar or Bipolar Depression: a Phase II Exploratory add-on Double Blind Placebo Controlled 2 Week Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tangent Data</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tangent Data</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effects of the nicotinic allosteric modulator JNJ-39393406 on psychometric&#xD;
      performance and residual depressive symptoms in patients who have been diagnosed with&#xD;
      unipolar and bipolar depression but currently DO NOT meet criteria for an episode of Major&#xD;
      Depression or Manic Episode.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the effects of the nicotinic allosteric modulator JNJ-39393406 on psychometric&#xD;
      performance and residual depressive symptoms in patients who have been diagnosed with&#xD;
      unipolar and bipolar depression but currently DO NOT meet criteria for an episode of Major&#xD;
      Depression or Manic Episode.&#xD;
&#xD;
      Hypothesis: Allosteric modulation of the a7nAChR with JNJ-39393406 improves psychometric&#xD;
      performance and residual depressive symptoms in patients with unipolar major depression&#xD;
      disorder (MDD) or bipolar depression (BPD).&#xD;
&#xD;
      Outcome measurements:&#xD;
&#xD;
        -  BACS&#xD;
&#xD;
        -  MADRS&#xD;
&#xD;
        -  BNSS&#xD;
&#xD;
        -  CGI-S- BP,&#xD;
&#xD;
        -  Questionnaire on smoking urges (QSU) and time to the first cigarette after waking up in&#xD;
           the morning,&#xD;
&#xD;
        -  Readiness for discharge scale.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effects of the nicotinic allosteric modulator JNJ-39393406 on cognition</measure>
    <time_frame>two weeks - each study visit</time_frame>
    <description>Brief Assessment of Cognition (BACS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of JNJ-39393406 on depressive symptoms</measure>
    <time_frame>two weeks - each study visit</time_frame>
    <description>Montgomery-Asberg Depression Scale (MADRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of JNJ-39393406 on residual depressive symptoms</measure>
    <time_frame>two weeks - each study visit</time_frame>
    <description>Brief Negative Symptoms Scale (BNSS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>JNJ-39393406</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-39393406</intervention_name>
    <description>JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial</description>
    <arm_group_label>JNJ-39393406</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Meet DSM V criteria for history of MDD or BPD by MINI.&#xD;
&#xD;
          2. Between 18-50 years of age, male or female subjects of any race, smokers and&#xD;
             non-smokers.&#xD;
&#xD;
          3. Able to provide informed consent. All participant patients must have signed an&#xD;
             informed consent document indicating they understand the purpose of the study and the&#xD;
             procedures required for the study and are willing to participate by complying with the&#xD;
             study procedures and restrictions.&#xD;
&#xD;
          4. Have a MADRS ≥ 10 and ≤ 34 and an YMRS &lt; 7.&#xD;
&#xD;
          5. In the opinion of the investigator, basic education and severity of symptoms&#xD;
             (psychotic, negative, manic, agitation, depression) do not prevent the patient from&#xD;
             attending to the cognitive tasks.&#xD;
&#xD;
          6. In the opinion of the investigator the patient can be safely treated with no more than&#xD;
             2 psychotropic medications as background therapy (SOS for agitation and sleeping&#xD;
             medication are allowed in addition to the 2 psychotropics).&#xD;
&#xD;
          7. The background psychotropic(s) that will be continued through-out the 2 week trial&#xD;
             must have been started at least 2 weeks prior to the baseline day at doses allowed by&#xD;
             the local regulations and no changes in dose have been made during this pre-baseline 2&#xD;
             week period.&#xD;
&#xD;
          8. Inpatients or out-patients at the discretion of the investigator (If outpatients the&#xD;
             Readiness for Discharge Scale has to be administered at baseline and at each visit.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women of child bearing potential who do not practice contraception.&#xD;
&#xD;
          2. Psychosis, florid manic or major depressive episode during the 4 weeks preceding&#xD;
             baseline day or current psychosis.&#xD;
&#xD;
          3. Patients on more than 2 psychotropic (hypnotics for sleep and occasional SOS for&#xD;
             agitation do not count).&#xD;
&#xD;
          4. Smokes more than 40 cigarettes per day.&#xD;
&#xD;
          5. Unstable medical disease (malignancy, poorly controlled diabetes, or cardiomyopathy,&#xD;
             serious pulmonary disease, kidney disease, impaired liver functioning. Particular&#xD;
             attention should be given to exclude patients with ischemic heart disease).&#xD;
&#xD;
          6. Has a clinically significant abnormal 12-lead electrocardiogram (ECG) at Screening&#xD;
             Visit 1 as determined by the Investigator.&#xD;
&#xD;
          7. At significant risk of committing suicide, or in the opinion of the Investigator,&#xD;
             currently is at imminent risk of suicide or harming others.&#xD;
&#xD;
          8. Patients with a current DSM-V substance or alcohol dependence.&#xD;
&#xD;
          9. Concurrent delirium, mental retardation, drug-induced psychosis, or history of stroke,&#xD;
             brain degenerative disorders and brain trauma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Davidson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Psychiatric Hospital</name>
      <address>
        <city>Codru</city>
        <zip>MD2011</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Stefi-Dent Srl</name>
      <address>
        <city>Botosani</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Psychiatry and Neurology</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spit. Clinic de Urgenta Militar &quot;Dr. Stefan Odobleja&quot;</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Moldova, Republic of</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 21, 2016</study_first_submitted>
  <study_first_submitted_qc>February 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2016</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

